Business
Social Capital Suvretta Holdings Corp. III Announces Reconvened Extraordinary General Meeting of Shareholders
PALO ALTO, Calif.--(BUSINESS WIRE)-- Social Capital Suvretta Holdings Corp. III (“SCS”) today announced that it will reconvene the Extraordinary General
About this update from Prokidney Corp.
[{"type":"text","content":" PALO ALTO, Calif.--(BUSINESS WIRE)--\nSocial Capital Suvretta Holdings Corp. III (“SCS”) today announced that it will reconvene the Extraordinary General Meeting of its shareholders to vote on the Business Combination Agreement, dated as of January 18, 2022, by and between SCS and ProKidney LP, a limited partnership organized under the laws of Ireland (“ProKidney”), acting through its general partner ProKidney GP Limited, a private limited company incorporated under the laws of Ireland, and the transactions contemplated thereby (the “Business Combination”) on July 11, 2022 at 8:30 a.m., Eastern Time, physically at the offices of Wachtell, Lipton, Rosen & Katz located at 51 West 52nd Street, New York, New York 10019, and virtually via live webcast at https://www.cstproxy.com/socialcapitalsuvrettaholdingsiii/2022.\n\nAbout Social Capital Suvretta Holdings Corp. III\n\nSocial Capital Suvretta Holdings Corp. III is led by Chamath Palihapitiya and Kishen Mehta and is a special purpose acquisition company formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company is focused on businesses operating in the biotechnology industry and within the organ space subsector. To learn more about Social Capital Suvretta Holdings, visit https://www.socialcapitalsuvrettaholdings.com/.\n\nAdditional Information and Where to Find It\n\nIn connection with the proposed transaction between SCS and ProKidney, SCS has filed a definitive proxy statement with the U.S. Securities and Exchange Commission (the “SEC”). SHAREHOLDERS OF SCS ARE ADVISED TO READ THE DEFINITIVE PROXY STATEMENT (INCLUDING ANY AMENDMENTS AND SUPPLEMENTS THERETO) AND ALL OTHER RELEVANT DOCUMENTS FILED OR THAT WILL BE FILED WITH THE SEC IN CONNECTION WITH THE PROPOSED TRANSACTION AS THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. The definitive proxy statement was mailed to the shareholders of SCS as of June 2, 2022, the record date established for voting on the proposed transaction. Shareholders are also able to obtain copies of the preliminary proxy statement, the definitive proxy statement and other documents filed with the SEC incorporated by reference therein, without charge, at the SEC’s website at http://www.sec.gov.\n\...